J9029 HCPCS code: Intravesical instillation, nadofaragene firadenovec-vncg, per therapeutic dose
J9029 is the HCPCS Level II code for intravesical instillation, nadofaragene firadenovec-vncg, per therapeutic dose. In 2024 Medicare paid an average of $33,976.08 per service for J9029 across 508 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 1 per day on outpatient hospital claims. Medicare volume rose 2319% from 2023 to 2024 (21 to 508 services). In 2024, about 177 clinicians billed Medicare for J9029 for 230 beneficiaries; Texas, Arizona, Florida accounted for 73% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1D — Chemotherapy |
| Added | 2023-07-01 |
| Last action effective | 2024-01-01 |
Who bills J9029 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 177 |
| Medicare beneficiaries | 230 |
| States with claims | 6 |
| Share of services in top 3 states (Texas, Arizona, Florida) | 73% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J9029, 2023–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2023 | 21 | 17 | $53,834.17 | $42,892.27 |
| 2024 | 508 | 230 | $42,644.92 | $33,976.08 |
States with the most J9029 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Texas | 107 | $15,257.84 |
| Arizona | 58 | $49,542.83 |
| Florida | 33 | $49,583.26 |
| Georgia | 33 | $49,004.92 |
| Tennessee | 21 | $49,604.94 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 1 | Prescribing Information |
| practitioner claims | 1 | Prescribing Information |
What changed for J9029
- 2023-07-01: J9029 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J9029?
J9029 is the HCPCS Level II code for intravesical instillation, nadofaragene firadenovec-vncg, per therapeutic dose. Short descriptor: "Instill adstiladrin, tx dose".
How much does Medicare pay for J9029?
In 2024, the average Medicare payment was $33,976.08 per service (average allowed $42,644.92).
Does Medicare cover J9029?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J9029 can be billed per day?
1 on outpatient hospital claims; 1 on practitioner claims (NCCI medically unlikely edits).
Related J90 codes
- J9000 — Injection, doxorubicin hydrochloride, 10 mg
- J9003 — Leuprolide injectable (camcevi etm), 1 mg
- J9010 — Injection, alemtuzumab, 10 mg
- J9011 — Injection, datopotamab deruxtecan-dlnk, 1 mg
- J9015 — Injection, aldesleukin, per single use vial
- J9017 — Injection, arsenic trioxide, 1 mg
- J9019 — Injection, asparaginase (erwinaze), 1,000 iu
- J9020 — Injection, asparaginase, not otherwise specified, 10,000 units
- J9021 — Injection, asparaginase, recombinant, (rylaze), 0.1 mg
- J9022 — Injection, atezolizumab, 10 mg
- J9023 — Injection, avelumab, 10 mg
- J9024 — Injection, atezolizumab, 5 mg and hyaluronidase-tqjs
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J9029
- Watch J9029 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J9029
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.